CBZ · CBIZ, Inc.

The thesis

CBIZ's $55.00-per-share cash sale to an affiliate of Grant Thornton Advisors is on track to close in the fourth quarter of 2026, so the shares have little room to beat the S&P 500 over the next three months. The special shareholder meeting on 27 October 2026 settles the last major condition. The adjusted daily close on 26 October 2026 was $54.85, 15 cents under the cash price.

The Hart-Scott-Rodino antitrust waiting period expired at 11:59 p.m. ET on 10 September 2026, per the 18 September 2026 definitive proxy. Approval needs a majority of all 54,940,482 shares outstanding on the 16 September 2026 record date. The board unanimously recommends the deal, and directors and executive officers own about 4.07% of the shares and intend to vote for it, per the proxy. No vote tally had been published at the time of writing.

The narrative is saturated: the terms are fully known, and the shares trade against a fixed cash price. William Blair cut CBIZ to Market Perform on 23 September 2026, saying a rival bid is materially less likely after the go-shop period ended on 27 August 2026.

Bullish and bearish views on CBIZ, Inc.

The bull case on CBIZ, Inc. (CBZ), in brief: Antitrust clearance is already in hand. The bear case: The cash price caps the upside.

Bull case

• Antitrust clearance is already in hand. The HSR waiting period expired on 10 September 2026, per the 18 September 2026 proxy. The proxy names no other pending regulatory approval.
• The company still expects a fourth-quarter close. CBIZ's third-quarter release on 19 October 2026 repeated that the deal should close in the fourth quarter of 2026, subject to shareholder approval and customary conditions. The company gave no full-year guidance and held no call.
• Third-quarter earnings improved. Revenue was $702 million, up 1.2%, and GAAP net income was $47 million, up 56.7%, per the 19 October 2026 results. Under a cash deal these figures matter mainly because they lower the chance of a closing dispute.
• The buyer owes a large break fee. The buyer's termination fee is $198.4 million, backed by a limited guarantee from Grant Thornton Advisors LLC, per the proxy. The 28 July 2026 merger disclosure reported $5.2 billion of committed financing.

Bear case

• The cash price caps the upside. The 26 October 2026 close of $54.85 sits below the $55.00 consideration, and the 52-week high is $55.50 in adjusted daily bars. A higher bid is unlikely after the go-shop ended, per William Blair on 23 September 2026.
• Approval needs a majority of all shares. The threshold counts every outstanding share, so shares that do not vote count against the merger.
• Quarterly results missed estimates. Adjusted earnings per share of $1.21 trailed the $1.29 estimate, and revenue of $702.24 million trailed the $720.549 million estimate, per a 19 October 2026 report on the results.
• A new legal charge surfaced late. In an 8-K on 22 October 2026, CBIZ disclosed about $15 million of additional one-time legal expense for the quarter, which it expects to cut net income by about $10.5 million after tax. The company excludes it from adjusted net income, adjusted diluted earnings per share and adjusted EBITDA.
• Control weaknesses remain on record. KPMG issued an adverse opinion on internal control over financial reporting as of 31 December 2025 in the 4 August 2026 amended annual report, and both material weaknesses were unremediated at filing. A restatement could test the merger's material-adverse-effect condition.

Price setup

The shares closed at $54.85 on 26 October 2026, 1.2% below the 52-week high of $55.50. The three-month price change is -0.1%, and the 14-day Relative Strength Index reads 60.0, down from 69.0 on 13 October 2026. The shares trade inside a few cents of the cash price, so their moves track the odds of completion and the time to closing.

Crowding evidence is thin on the buying side. Barrington Research and William Blair both downgraded the shares to Market Perform in September, and no analyst upgrade has followed. The next scheduled event is the shareholder vote, which settles whether the price stays near $55.00 or reprices toward the pre-deal level.

Catalysts, next 30 days

• ~9 November 2026 (est.): Quarterly report on Form 10-Q, expected to carry the $15 million legal charge and an update on the two control weaknesses.
• ~31 December 2026 (est.): End of the company's expected fourth-quarter closing window. At closing, holders receive $55.00 in cash and the shares leave the NYSE.

Elapsed catalysts

• 27 October 2026: Special meeting of stockholders at 8:00 a.m. ET to vote on the merger. Approval clears the last major closing condition. A rejection or an adjournment for lack of votes breaks the completion case. (passed 4d ago)
• ~28 October 2026 (est.): Form 8-K reporting the vote counts, normally filed within four business days of the meeting. It shows how far the vote cleared the majority-of-outstanding-shares threshold. (passed 3d ago)

What would change the view

The case breaks if shareholders reject the merger or the meeting is adjourned without approval. It also breaks if a filing terminates the 28 July 2026 merger agreement, if the closing window moves past the fourth quarter of 2026, or if the 10-Q discloses a restatement or a merger amendment tied to the accounting findings. A daily close below $52 would show the market pricing real risk to the cash deal.

A higher rating would need a competing proposal or an amended price above $55.00, and none has appeared since the go-shop ended.

What it trades with

The shares trade on the odds of deal completion and the time to closing, so their link to the S&P 500 and to accounting-services peers is weak while the $55.00 cash price holds. Financing conditions for large leveraged buyouts, including the $5.2 billion of committed financing, are the broader channel that could matter. If the deal breaks, the shares would likely return to trading on their own earnings and sector multiples.